beta2-adrenoreceptor agonists, montelukast, and Parkinson's disease risk. Liu B, Svenningsson P, Ludvigsson JF, Lundholm C, et al. Ann Neurol 2023 Mar 10. doi: 10.1002/ana.26638.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Liu B, Svenningsson P, Ludvigsson JF, Lundholm C, et al. beta2-adrenoreceptor agonists, montelukast, and Parkinson's disease risk. Ann Neurol 2023 Mar 10. doi: 10.1002/ana.26638.
PMID: 36897287